Every 8-K that Wellgistics Health Inc. (WGRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow WGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGRX filings page.
DataMEDS AI, Inc. entered into an Amended and Restated Letter of Intent with EOS Technology Holdings, Scilex Holding Company, Datavault AI Inc., and HealthBridge Advisors to negotiate a stock-based transaction. The contemplated deal would acquire or exclusively license QOLPOM/QLPM intellectual property from EOS and Scilex, expand the existing PharmacyChain license to include Datavault AI Health, and obtain a controlling interest in Tollo Health, LLC through an exchange of membership interests with HealthBridge Advisors.
The parties expect new investors and partners to hold approximately 84.6% of common stock on a fully diluted, post-closing basis, with Fortitude Advisors at about 5% and existing public stockholders at about 10.4%, subject to detailed capitalization modeling and multiple adjustments. The LOI includes liability reduction and financing frameworks, six‑month post-closing lock-ups for certain holders, and a registration rights agreement requiring resale registration of Acquisition Stock within 45 days of closing. Closing remains subject to due diligence, definitive agreements, a fairness opinion, corporate and stockholder approvals, financing, Nasdaq requirements (including potential change-of-control treatment), and other customary conditions, and there is no assurance the transaction will be completed.
DataMeds AI, Inc. updated the record date for its planned distribution of the Dream Bowl 2026 Meme Coin to stockholders to August 7, 2026. Holders of common stock on that date are entitled to receive 50 DREAM coins per share, compared with the previously announced distribution of one coin per share.
The distribution date will be set later in coordination with DataVault AI. As of this announcement, the company has 2,847,198 common shares outstanding; about 1,533,930 shares are subject to 90‑day lock-up agreements, while 919,465 shares are held at DTCC and available for trading. DataMeds also reports 80,826 outstanding cash warrants with a $35.00 exercise price and no currently convertible debt or preferred equity.
Wellgistics Health, Inc. received an extension from Nasdaq to regain compliance with the stockholders’ equity listing standard after previously reporting stockholders’ equity of $(12,447,801) as of December 31, 2025, below the $2,500,000 minimum. The company is pursuing transactions with DataVault AI and Tollo Health and estimates a potential combined asset value of $4 billion and post-transaction stockholders’ equity of about $40 million.
Nasdaq’s letter allows Wellgistics until October 12, 2026 to demonstrate equity compliance through one of two reporting alternatives that include detailed disclosure and, if used, a pro forma balance sheet evidencing sufficient equity. Separately, Nasdaq confirmed the company has regained compliance with the $1.00 minimum bid price requirement after its common stock closed at or above that level for each business day from May 26, 2026 to June 8, 2026, so that matter is now closed.
Wellgistics Health, Inc. filed an amendment to a prior current report to update a single exhibit. Amendment No. 2 replaces and refiles Exhibit 4.3, described as the Form of Placement Agent Warrant that was previously included with Amendment No. 1. The company states that no other disclosures or exhibits from the original report or Amendment No. 1 are modified, and the amendment does not reflect any subsequent events.
Wellgistics Health, Inc. completed a $21 million convertible debt financing that refinances all of its previously outstanding convertible debt and raises $6.5 million in new capital for operations. The new, oversubscribed instrument does not accrue interest and converts into common shares at $6.00 per share.
The New Debt includes an automatic exchange into a new class of Preferred Stock once a registration statement is effective and stockholders approve the creation of preferred stock. That Preferred Stock converts into common shares at $50.00 per share, and the company notes the transaction may result in substantial future dilution to existing stockholders.
Wellgistics Health, Inc. entered into a financing on May 27, 2026, issuing 0% convertible promissory notes with an aggregate principal amount of $21,132,812.50 for cash proceeds of $16,906,250, reflecting a 20% original issue discount, and accompanying PIPE warrants.
The notes are initially convertible into common stock at the lesser of $6.00 per share or the prior-day closing price, with a $1.00 floor, and will later automatically convert into Series A Convertible Preferred Stock once specified stockholder and charter approvals and a resale registration are effective. PIPE warrants are exercisable at $7.50 per share until May 27, 2031, with total potential gross proceeds of about $42.8 million if all PIPE and placement agent warrants are exercised for cash at initial prices.
The company used part of the proceeds to repay approximately $1.77 million of debt owed to Marco Capital, Inc., and secured lock-up agreements covering 1,333,930 common shares, representing a majority of outstanding shares, restricting sales for at least 90 days under specified conditions.
Wellgistics Health, Inc. released a shareholder letter outlining a major strategic shift toward vertically integrated, blockchain-based healthcare infrastructure. Management explains how recent transactions are meant to connect data, verification, and patient engagement across its EinsteinRx™ AI platform and PharmacyChain™ smart-contract system.
The Company highlights formation of DelivMeds AI and an expanded Datavault license to support tokenized healthcare data, acquisition plans for the QOLPOM patent portfolio to add biometric verification and medical drone capabilities, and a controlling interest in Tollo Health with its Forzet™ offering. Through the Health Lives Here program with NFL Alumni Health, Wellgistics aims to gather real-world GLP-1 patient data that feeds back into its platform.
Wellgistics notes it already connects more than 6,500 pharmacies and 200+ manufacturers and views the pharmacy as a key data and adherence touchpoint. The letter also references a planned share restructuring and new CUSIP and includes extensive forward‑looking statements about revenue expectations, app launch timing, platform integration, and regulatory and execution risks.
Wellgistics Health, Inc. entered into a fully binding letter of intent with Datavault AI, EOS, Scilex, HealthBridge Advisors and Fortitude Advisors for a multi‑step transaction that would contribute healthcare data, drone logistics and consumer health assets into the company. The parties target an approximate combined asset value of $4.0 billion, subject to an independent fairness opinion and numerous approvals and financing conditions.
The structure would use new preferred stock convertible into common shares so that these counterparties are expected to own about 89.6% of the common stock after conversion, with existing public stockholders retaining about 10.4%, subject to adjustment. Wellgistics also amended a note purchase agreement, increasing the investor’s cash funding to $1.2 million and the related note’s principal to $1.5 million. Separately, the board and stockholders approved a 1‑for‑50 reverse stock split, reducing outstanding shares from roughly 125.7 million to about 2.5 million to help regain Nasdaq minimum bid‑price compliance.
Wellgistics Health, Inc. reported first quarter 2026 results showing rapid revenue growth and a much smaller loss. Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results.
Company revenue was $0.486 million in Q4 2025 and $0.929 million in Q1 2026, and the Company expects revenue of $1.775 million in Q2 2026. Net operating loss narrowed to $7.742 million in the quarter ended March 30, 2026 from $32.430 million a year earlier, with loss per share improving to $0.07 from $0.62.
Management highlighted cost reductions, a Kare Pharmtech joint venture providing access to over 200,000 patient lives, an expanded partnership with Tollo Health, added capabilities such as insurance eligibility verification, and a growing focus on GLP-1 related opportunities and PharmacyChain™/EinsteinRx™ integration.
Wellgistics Health, Inc. filed an 8-K to state that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026 after the market closes. The information is furnished under Regulation FD, meaning it is provided for disclosure purposes and not deemed filed under securities laws.
The company describes itself as a health information technology and pharmaceutical distribution business that integrates its EinsteinRx AI pharmacy optimization platform with its blockchain-enabled PharmacyChain smart contracts platform. This network links more than 6,500 pharmacies and over 200 manufacturers to support distribution, prescription routing, direct-to-patient delivery, and AI-powered hub services.
The accompanying press release also includes forward-looking statements about a proposed acquisition of WellCare Today, LLC and potential integration of remote monitoring and care-coordination technologies, while highlighting numerous regulatory, financing, operational, and reimbursement risks that could cause actual outcomes to differ.
Wellgistics Health, Inc. reported that it has requested withdrawal of its Preliminary Proxy Statement on Schedule 14A related to a planned special meeting of stockholders. The company decided not to move forward with those preliminary proxy materials as it continues to evaluate potential strategic transactions.
Wellgistics noted that it may file revised proxy materials at a later date once its review progresses. No definitive proxy materials connected to the withdrawn preliminary proxy statement were mailed or otherwise distributed to stockholders.
Wellgistics Health, Inc., through its subsidiary Wellgistics, LLC, entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement with Marco Capital, Inc. on May 1, 2026. Wellgistics acknowledged approximately $1.77 million in outstanding obligations under a prior Loan and Security Agreement.
Under the Forbearance Agreement, Marco Capital agreed to temporarily forbear from exercising certain rights and remedies through June 15, 2026. Wellgistics must make bi-weekly payments of $50,000 starting May 5, 2026, and a portion of net proceeds from future financings during the forbearance period may need to be applied to repayment. The obligations will accrue interest at a rate equal to Term SOFR plus 11.5% per annum beginning May 5, 2026.
Wellgistics Health, Inc. filed an amended current report to correct the cover-page report date to February 9, 2026 and to restate its description of a key contract. The company explains that the material definitive agreement for disclosure purposes is an Amended Settlement Agreement entered on February 9, 2026 with Silverback Capital Corporation, which modifies an earlier settlement agreement referenced in the original report. All other disclosures from the original report remain unchanged.
Wellgistics Health, Inc. filed an amended report describing a new joint venture with Kare Pharmtech affiliates and a Nasdaq listing deficiency notice. The company agreed to form Healthstar Technologies, LLC, holding a 51% membership interest while Kare Rx Hub holds 49%.
In exchange for Kare Rx Hub transferring certain intellectual property and related assets to Healthstar, Wellgistics will pay Kare Pharmtech $2,000,000 in common stock, including 1,500,000 shares at closing and potential additional shares by April 1, 2027, based on a two-day volume-weighted average price. These unregistered shares will be restricted and subject to a 12‑month lock-up. Closing is conditioned on satisfactory due diligence, with either side able to terminate if dissatisfied.
Separately, Nasdaq notified Wellgistics that it is not in compliance with Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. The company reported stockholders’ equity of $(12,447,801) and also does not meet alternative continued listing standards. Wellgistics has until May 28, 2026 to submit a compliance plan and may receive up to 180 days from April 13, 2026 to regain compliance if Nasdaq accepts that plan.
Wellgistics Health, Inc. entered into a Collaboration Agreement to form a new limited liability company, Healthstar, with Kare Rx Hub, LLC. Wellgistics will hold a 51% membership interest and Kare Hub will hold 49%. Kare Hub will transfer specified intellectual property and related assets into Healthstar.
As consideration, Wellgistics agreed to pay Kare Pharmtech an aggregate purchase price of $2,000,000 in unregistered common stock. The agreement provides for 1,500,000 shares at closing and, at Wellgistics’ option, additional shares by April 1, 2027, based on a two-day volume-weighted average price. The Purchase Shares will be restricted, with Kare Pharmtech subject to a 12‑month lock-up from each payment date.
A related press release explains that the joint venture combines Wellgistics’ EinsteinRx™ and HubRx AI™ platforms with KareRx’s digital hub, creating an integrated ecosystem that can potentially reach more than 200,000 patient lives and support direct‑to‑patient and decentralized care models.
Wellgistics Health, Inc. terminated a prior Settlement Agreement with Silverback Capital Inc. that had allowed it to issue common stock under Section 3(a)(10) of the Securities Act. Before termination, the company issued 6,866,000 shares under this structure. The agreement is no longer in effect, no additional shares will be issued under it, and Silverback has been asked to return all rights to unpaid claims to the relevant creditors. Wellgistics elected to end this settlement structure to pursue alternative strategic and financing initiatives, which the company states eliminates potential future dilution tied to the Settlement Agreement.
Wellgistics Health, Inc. entered into a Note Purchase Agreement on April 1, 2026 to issue and sell up to $1,250,000 in aggregate principal amount of promissory notes in a private offering. Investors will pay $1,000,000, reflecting a 20% original issue discount.
The Notes bear 0% interest unless an event of default occurs, in which case interest increases to 15% per year. All principal and any default interest are due on the earlier of 12 months from issuance or the closing of a Qualified Financing. While the notes are outstanding, the company has agreed not to incur additional borrowed money debt or grant new liens, and investors receive the right to participate in future securities offerings up to 100% of their note principal.
Wellgistics Health, Inc. entered a three-year Interim Commercialization and Revenue Share Agreement with Kare PharmTech to market, promote and distribute Kare’s KARE Verify eligibility and benefits verification product through Wellgistics’ pharmacy and distribution network.
All net revenue from KARE Verify will be split 50% to Wellgistics and 50% to Kare PharmTech. Wellgistics also secured preferred pricing for medical insurance eligibility and benefits verification services, which it plans to offer immediately via its EinsteinRx AI hub and later integrate into its PharmacyChain platform to support a new revenue stream starting in the second quarter of 2026. The EBV market is cited as growing from $2.39 billion in 2025 to $3 billion in 2030.
Wellgistics Health, Inc. filed a current report highlighting the launch of Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies, including GLP-1 agonist drugs such as Ozempic, Wegovy and Mounjaro.
Forzet is classified as a medical food, is available over the counter, does not require a prescription, and is intended for use under physician supervision. It has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe.
Wellgistics plans to recommend Forzet through its EinsteinRx AI pharmacy hub via point-of-sale pop-ups in its 6,500+ pharmacy network and to feature GLP-1 drugs and Forzet in its growing direct-to-consumer and telehealth offerings. The press release notes estimates that the GLP-1 agonist market could grow from $70 billion in 2025 to $201 billion in 2030.
Wellgistics Health, Inc. entered a court-approved settlement with Silverback Capital Corporation to resolve at least $10,712,734.16 of company liabilities through the issuance of common stock under a Section 3(a)(10) exemption. A Florida court approved the fairness of both the settlement terms and related share issuances.
The settlement allows shares to be issued in tranches by dividing portions of the claim amount by fixed prices between $0.25 and $2.25 per share, with the first $2,250,000 tranche set at $0.25 per share. Wellgistics also agreed to issue 100,000 shares as a settlement fee and 300,000 shares for legal fees. Separately, the company appointed Fortitude Advisors, owned and controlled by Gerald Commissiong, as consulting Chief Business Officer, and announced an expanded partnership with Tollo Health’s TolloCare unit to add GLP-1 and Long COVID telehealth services and a mental health AI app to its platform.
Wellgistics Health, Inc. elected Gary Herman as an independent director effective February 4, 2026, and named him chairman of the Audit Committee. Non‑employee directors receive a $120,000 annual cash retainer, an annual equity award of 60,000 shares of Common Stock, and 200,000 restricted shares vesting over three years at appointment.
The company also entered into an agreement with NFL Alumni Health to develop healthcare and wellness programs using its EinsteinRx AI pharmacy hub and PharmacyChain blockchain platform. The programs will start with former NFL players, then expand to rural communities through a network of more than 6,500 independent pharmacies, focusing on mental health, weight loss, sleep apnea, cardiometabolic disease, pain management, and Long COVID.
Wellgistics Health, Inc. reported that two members of its board of directors resigned effective February 1, 2026. Steven Lee resigned from the board and his role on the Ethics Committee, and Howard Doss resigned from the board and his role as chairman of the Audit Committee.
Both directors stated that their decisions to step down were not the result of any disagreement with the company regarding its operations, policies, or practices. The company also filed their formal resignation letters as exhibits to this report.
Wellgistics Health, Inc. entered into a private offering of secured convertible promissory notes with certain investors, agreeing to issue up to $8,125,000 in aggregate principal amount for an aggregate purchase price of $6,500,000, reflecting a 20% original issue discount. The notes mature on the earlier of six months from issuance or the closing of a Qualified Financing and carry a 0% interest rate unless an event of default occurs, when the rate increases to 18% per annum.
Holders may elect to convert outstanding amounts into common stock at a conversion price of $0.4057 per share. The notes are guaranteed by a subsidiary and secured by the assets of the company and its wholly owned subsidiaries under a security agreement and an intellectual property security agreement. While the aggregate principal amount remains outstanding, the company is restricted from incurring new borrowed money or new liens other than on its intellectual property, and investors receive rights to participate in future offerings. Wellgistics engaged Dawson James Securities, Inc. as placement agent, paying a 6.5% selling commission on gross proceeds and issuing warrants equal to 5% of the aggregate gross proceeds, with an exercise price set at the common stock’s closing price before the offering closed.
Wellgistics Health, Inc. entered into a note purchase agreement to issue and sell up to $3,125,000 in aggregate principal amount of convertible promissory notes in a private offering, for an aggregate purchase price of $2,500,000 reflecting a 20% original issue discount. The notes carry 0% interest unless a default occurs, when the rate increases to 18% per year, and mature on the earlier of six months after issuance or the closing of a qualified financing of at least $2,000,000. Holders may elect to convert outstanding amounts into the equity securities sold in such a qualified financing, at the financing price but not below a floor price of $0.08 per share, which was set to avoid issuing more than 20% of the company’s capitalization. A subsidiary guarantees all amounts due, investors receive participation rights in future offerings up to 100% of their note principal, and the company agreed to restrictions on incurring additional debt or new liens while the notes remain outstanding. Wellgistics paid $162,500 in selling commissions and issued placement agent warrants equal to 5% of gross offering proceeds to Dawson James Securities, Inc.
Wellgistics Health, Inc. reports that it received a notice from Nasdaq on December 10, 2025 stating that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days through December 9, 2025, as required under Nasdaq Listing Rule 5550(a)(2).
Nasdaq has granted an initial compliance period until June 8, 2026 for the company to regain compliance, with the possibility of an additional 180-day period if other listing standards are met and a reverse stock split is used if necessary. The shares will continue trading on The Nasdaq Capital Market under the symbol WGRX for now, but the company notes that its stock could be delisted if bid price compliance is not restored.
Wellgistics Health, Inc. filed a current report stating that on December 4, 2025 it issued a press release, which is furnished as Exhibit 99.1. The company classifies this information under Regulation FD, meaning it is being shared to keep public disclosure consistent and broad. The exhibit is expressly described as furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.
The report also highlights that the press release contains forward-looking statements about projects, potential financial performance, and growth opportunities. These statements are subject to risks and uncertainties described in the company’s SEC filings, including its Registration Statement on Form S-1 that was declared effective on September 25, 2025. Wellgistics notes it has no obligation to update these forward-looking statements after the date of the press release.
Wellgistics Health, Inc. (WGRX) disclosed that on November 26, 2025, it entered into a sponsorship agreement with Cutting Edge Sports Management, LLC (CESM). Under the agreement, Wellgistics will pay a sponsorship fee of $250,000 in exchange for sponsorship benefits and assets at Dream Bowl XIV in Arlington, Texas, scheduled for January 8–11, 2026, including broadcasting and branding opportunities and access to certain CESM intellectual property.
The sponsorship term runs from execution of the agreement through February 15, 2026. The company also noted it issued a press release on November 24, 2025, which is furnished (not filed) as an exhibit and includes forward-looking statements subject to the usual risk factors described in its SEC filings.
Wellgistics Health, Inc. (WGRX) filed an amended report to update a previously issued press release and detailed a new license agreement with DataVault AI Inc. covering intellectual property for its PharmacyChain™ manufacturer-to-patient blockchain smart contract platform.
Under the License Agreement dated November 24, 2025, Wellgistics will pay a non-refundable fee of $2,500,000 by December 31, 2025. The company will also pay DataVault a 13% royalty on all net profit from use of the licensed technology, with a minimum annual royalty of $1,000,000 starting in 2028 if PharmacyChain™ generates at least $2,000,000 in annual net profit in 2028 or 2029. Wellgistics may grant sublicenses but must remit 90% of net revenue from any sublicenses to DataVault.
Wellgistics Health, Inc. entered into a long-term license agreement with DataVault AI Inc. to use certain intellectual property for its PharmacyChain™ platform, which aims to create manufacturer-to-patient blockchain-enabled smart contracts for the prescription drug industry.
Wellgistics will pay DataVault a non-refundable license fee of $2,500,000 by December 31, 2025. The company will also pay a 13% royalty on all net profit generated from use of the licensed technology, with payments due monthly.
Beginning in the 2028 calendar year, the agreement includes a minimum annual royalty of $1,000,000, with the 2028 and 2029 minimums applying only if PharmacyChain™ achieves at least $2,000,000 in annual net profit in the respective year. Wellgistics may sublicense the technology but must remit 90% of net revenue from any sublicenses to DataVault, paid quarterly.
Wellgistics Health, Inc. (WGRX) filed a Form 8-K to announce that it issued a press release reporting its financial results for the quarter ended September 30, 2025. The press release, dated November 20, 2025, is furnished as Exhibit 99.1 to the report.
The company notes that the press release includes forward-looking statements about its projects, potential financial performance, and growth opportunities, which are subject to risks and uncertainties described in its SEC filings, including its Form S-1 declared effective on September 25, 2025. The information in Items 2.02 and 7.01 is being furnished, not filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other SEC filings.
Wellgistics Health, Inc. reported that its independent auditor, UHY LLP, resigned as the company’s independent accountants effective November 11, 2025. UHY stated it elected to resign in light of certain information identified in the resignation of the former Chief Executive Officer, which had not yet been investigated, and it did not audit any of the company’s financial statements before resigning.
The company states there were no disagreements with UHY on accounting principles, financial statement disclosure, or audit procedures, and no additional reportable events beyond previously disclosed material weaknesses in internal control over financial reporting. These weaknesses include an underdeveloped control environment, limited documentation of policies and procedures, lack of evidence of control performance, and limited accounting personnel. The Audit Committee has approved re-engaging Suri & Co. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Wellgistics Health (WGRX) reported capital-structure changes. Holders exercised warrants at an exercise price of $0.70 per share, resulting in the issuance of 3,111,429 shares of common stock.
The company also entered two debt conversion agreements on October 30, 2025. It converted $1,300,000 of indebtedness into 1,857,143 shares at $0.70 per share, and converted $4,019,859 of indebtedness into 5,742,656 shares at $0.70 per share, in each case in full satisfaction of the underlying obligations.
Wellgistics Health, Inc. (WGRX) furnished a press release as Exhibit 99.1 under Item 7.01 (Regulation FD). The company notes the information is furnished and not deemed filed for Section 18 purposes or incorporated by reference. The release includes forward-looking statements and cautions that actual results may differ due to risks described in SEC filings, including the company’s Registration Statement on Form S-1 declared effective on September 25, 2025.
Wellgistics Health (WGRX) announced a non-binding letter of intent with DataVault to explore integrating PharmaChain, a manufacturer-to-patient blockchain-enabled smart contract solution, into Wellgistics’ technology and physical infrastructure for the prescription drug industry.
The contemplated collaboration would focus on digitizing prescription fulfillment workflows with a potential revenue-sharing arrangement, but economic and other material terms remain under negotiation and there is no assurance any agreement or revenues will result. The companies stated the contemplated solution does not involve tokens or digital assets. A joint press release was furnished as Exhibit 99.1.
Wellgistics Health, Inc. filed a Form 8-K under Item 7.01 (Regulation FD) to furnish a press release dated October 13, 2025 as Exhibit 99.1.
The company states the furnished information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference. The press release contains forward-looking statements, and readers are directed to risk disclosures in the company’s SEC filings, including its Form S-1 declared effective on September 25, 2025.
Wellgistics Health, Inc. reported that three senior executives resigned on October 6, 2025. Chief Executive Officer Brian Norton and Chief Financial Officer Mark DiSiena each resigned effective 5:00 p.m. EST, and Chief Operating Officer Tony Madsen resigned effective 8:00 p.m. EST the same day.
On October 7, 2025, the board appointed Eric Sherb as interim Chief Financial Officer. Sherb, age 38, is a CPA with 16 years of experience in accounting advisory, auditing, mergers and acquisitions, and capital markets transactions including IPOs and SPAC deals.
The company had previously entered into a consulting agreement on September 8, 2025 with EMS Consulting Services, Inc., an entity controlled by Sherb, which was amended to cover his interim CFO role. Under this agreement, he provides CFO-level services at hourly rates of $185 for CPA services and $80 for bookkeeping or controller-related work, and the agreement may be terminated by either party at any time.
Wellgistics Health, Inc. reported the immediate removal of two directors from its board. The filing states that Rebecca Shanahan and Michael Peterson were removed as directors effective immediately. At the time of their removals, Ms. Shanahan served on the Ethics Committee and Mr. Peterson served as the chair of the Audit Committee. The notice appears as a concise disclosure of governance changes without additional explanation of reasons, replacements, or related corporate actions.
Wellgistics Health, Inc. filed a current report to share investor communications it is using at upcoming events. On September 5, 2025, the company issued a press release announcing that it will present at three business conferences during September 2025, and that release is furnished as Exhibit 99.1.
The company is also providing an updated corporate presentation and a fact sheet, furnished as Exhibits 99.2 and 99.3, which it plans to use at these conferences and in future meetings with prospective investors and strategic partners. These materials, dated September 8, 2025, have been posted to the company’s investor website.
The press release, presentation, and fact sheet are furnished rather than filed, so they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings. The company emphasizes that these materials contain forward-looking statements and refers readers to its Form 10‑K and subsequent Form 10‑Q filings for a detailed discussion of related risks.
Wellgistics Health, Inc. entered into a Business Loan and Security Agreement with Agile Capital Funding, LLC for a principal amount of $1,300,000. The Agile Loan is effective as of August 26, 2025, matures on April 8, 2026, carries an interest charge of $572,000 assuming timely payments, and is to be repaid in weekly installments of $58,500. A portion of the loan was used to satisfy previously outstanding obligations with Agile Capital Funding, and the company received approximately $500,000 in cash proceeds, which it plans to use for general working capital. The loan is secured by certain company assets not otherwise pledged in other arrangements.
Separately, the company issued a press release on August 27, 2025 announcing the introduction of a fully customizable artificial intelligence engine integrated into its tech and hub platform. This press release is furnished as an exhibit and includes forward-looking statements subject to risks described in the company’s SEC reports.
Wellgistics Health, Inc. filed a current report to furnish a press release announcing its financial results for the second fiscal quarter ended June 30, 2025. The release, dated August 20, 2025, is attached as Exhibit 99.1 and is incorporated by reference into the disclosure items describing the results and related information.
The company specifies that the press release and related disclosures are being furnished, not filed, so they are not subject to certain liability provisions under the Securities Exchange Act and are not automatically incorporated into other securities law filings.
Wellgistics Health, Inc. reports two major corporate updates. The company terminated its equity purchase agreement with Hudson Global Ventures, which had allowed it to direct the investor to buy up to $50,000,000 of Wellgistics common stock, and states that it incurred no termination fees or penalties when it ended this financing arrangement.
The company also discloses that on August 8, 2025, President and director Prashant Patel resigned from both roles, with his employment agreement ending the same day. His resignation is described as not arising from any dispute or disagreement over operations, policies, or practices. Wellgistics further notes press releases announcing the launch of its XRP Implementation Program and the termination of the equity line facility.